Filtered By:
Condition: Diabetes
Nutrition: Sodium

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 371 results found since Jan 2013.

Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-Of-The-Art Review
Cardiovasc Hematol Agents Med Chem. 2021 Aug 9. doi: 10.2174/1871525719666210809121016. Online ahead of print.ABSTRACTSodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of anti-diabetic agents that block the reabsorption of glucose in the proximal convoluted tubule of the nephron, thereby contributing to glycosuria and lowering blood glucose levels. SGLT2 inhibitors have been associated with improved cardiovascular outcomes in patients with diabetes, including a reduced risk of cardiovascular death and hospitalizations for heart failure. Recently, DAPA-HF and EMPEROR REDUCED trials showed the beneficial cardiova...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - August 9, 2021 Category: Cardiology Authors: Mauro Gitto Dimitrios A Vrachatis Gianluigi Condorelli Konstantinos Papathanasiou Bernhard Reimers Spyridon Deftereos Giulio G Stefanini Source Type: research

Prescribing of SGLT2 inhibitors in primary care: a qualitative study of General Practitioners and Endocrinologists
In 2015, the EMPA-REG OUTCOME trial reported that treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, significantly reduced the risk of the primary composite outcome – death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke in patients with type 2 diabetes at high cardiovascular risk [1]. Since that landmark trial, many other large randomised controlled trials (RCTs) have confirmed the cardiovascular (particularly with respect to he art failure) and renal benefits of this drug class [2–7].
Source: Diabetes Research and Clinical Practice - September 2, 2021 Category: Endocrinology Authors: Tamara Y. Milder, Sophie L. Stocker, Melissa Baysari, Richard O. Day, Jerry R. Greenfield Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
This study compared dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and dipeptidyl peptidase-4 inhibitors (DPP-4i) with regard to cardiovascular (CV) event incidence and direct medical costs during type 2 diabetes treatment. A retrospective cohort study was conducted using national health insurance claims data from September 1, 2014, to June 30, 2018, of patients in Korea. Patients who were prescribed dapagliflozin and DPP-4i for the first time were included. The primary outcome was the incidence of a composite of major adverse CV events (MACEs)—nonfatal myocardial infarction, nonfatal stroke, or in-hospital ...
Source: Frontiers in Pharmacology - September 28, 2021 Category: Drugs & Pharmacology Source Type: research

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2-is might suppress atherosclerotic processes and ameliorate the prognosis of patients with diabetes mellitus diagnosed with or at high risk of atherosclerotic cardiovascular disease (ASCVD). In this mini review, we examine the role of SGLT2-is in the development and progression of atherosclerosis throughout its spectrum, from subclinical atherosclerosis to ASCVD.Data Sources—PubMed and Google Scholar were searched for publications related to...
Source: Frontiers in Pharmacology - November 5, 2021 Category: Drugs & Pharmacology Source Type: research

Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
AbstractSodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease. These cardiovascular and renal benefits have now been confirmed in both diabetes and non-diabetes patients. The precise mechanism(s)...
Source: Cardiovascular Drugs and Therapy - November 10, 2021 Category: Cardiology Source Type: research

Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up
Conclusion: In T2DM patients, the SGLT2-I significantly reduced the inflammatory burden and ameliorated clinical outcomes at 5 years of follow-up post-CABG via MiECC.
Source: Frontiers in Pharmacology - November 15, 2021 Category: Drugs & Pharmacology Source Type: research

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect
Eur J Intern Med. 2021 Nov 16:S0953-6205(21)00383-6. doi: 10.1016/j.ejim.2021.11.008. Online ahead of print.ABSTRACTFindings from cardiovascular outcome trials on certain newer glucose-lowering drugs have shown clear cardiovascular and renal benefits. In this review, we provide an updated overview of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors in terms of cardiovascular and renal protection. Both drugs have been described as diabetes/disease-modifying drugs. There is robust evidence on the benefits of GLP-1 receptor agonists in renal disease and atherosclerotic c...
Source: European Journal of Internal Medicine - November 20, 2021 Category: Internal Medicine Authors: Ricardo G ómez-Huelgas Jaime Sanz-C ánovas Lidia Cobos-Palacios Almudena L ópez-Sampalo Luis M P érez-Belmonte Source Type: research

Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure
Ong et al. have shown in their very informative, recently published meta-analysis that sodium-glucose co-transporter-2 (SGLT-2) inhibitors result in a significant decrease in the odds for atrial fibrillation (AF) regardless of status of diabetes mellitus or cardiovascular disease at baseline.1 However, the authors failed to show that this effect is sustained in subjects with heart failure (HF).1
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2021 Category: Neurology Authors: Dimitrios Patoulias, Christodoulos Papadopoulos, Michael Doumas Tags: Letter to the Editor Source Type: research

Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
AbstractSodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease. These cardiovascular and renal benefits have now been confirmed in both diabetes and non-diabetes patients. The precise mechanism(s)...
Source: Cardiovascular Drugs and Therapy - December 1, 2021 Category: Cardiology Source Type: research

Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction
CONCLUSION: Sodium ozagrel with atorvastatin can reduce inflammatory reactions; regulate ESR and HMGB1, PON-1, and MIF levels; control blood glucose and lipid indexes; and alleviate nerve injury without increasing adverse effects of atorvastatin alone.PMID:35047123 | PMC:PMC8696649 | DOI:10.4239/wjd.v12.i12.2096
Source: Atherosclerosis - January 20, 2022 Category: Cardiology Authors: You Yu Lin Wang Xu Zhu Ya-Fei Liu Hai-Ying Ma Source Type: research

' Chipping away ' at the iceberg of health disparities
'Chipping away' at the iceberg of health disparities Kelly Palmer joined the Mel and Enid Zuckerman College of Public Health faculty in January, not long after earning her doctorate from the college. As a researcher studying diseases that disproportionately affect Black women, Palmer says her work is a team effort – and incredibly personal. Kyle Mittan Today University CommunicationsPalmer-web.jpg"Black women are my mother, my sister, my cousin, the members of my sorority, Alpha Kappa Alpha," said Kelly Palmer, an assistant professor in the University of Arizona Mel and Enid Zuckerman College of P...
Source: The University of Arizona: Health - February 14, 2022 Category: Universities & Medical Training Authors: mittank Source Type: research

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
Biosci Rep. 2022 Mar 31;42(3):BSR20212209. doi: 10.1042/BSR20212209.ABSTRACTDiabetes mellitus is a chronic metabolic disease that occurs when the pancreas is not producing enough insulin or when the insulin that it does produce is not able to be used effectively in the body. This results in hyperglycemia and if the blood sugars are not controlled, then it can lead to serious damage of various body systems, especially the nerves and the blood vessels. Uncontrolled diabetes is a major cause of kidney failure, heart attacks, stroke and amputation. One of the most devastating complications for patients is diabetic retinopathy ...
Source: Bioscience Reports - March 2, 2022 Category: Biomedical Science Authors: Jennifer Matthews Lakshini Herat Jennifer Rooney Elizabeth Rakoczy Markus Schlaich Vance B Matthews Source Type: research